JPMorgan Chase & Co. Sells 8,362,010 Shares of Omnicell, Inc. $OMCL

JPMorgan Chase & Co. decreased its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 94.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 515,352 shares of the company’s stock after selling 8,362,010 shares during the quarter. JPMorgan Chase & Co.’s holdings in Omnicell were worth $15,692,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. WINTON GROUP Ltd bought a new position in Omnicell during the second quarter worth $2,692,000. Advantage Alpha Capital Partners LP bought a new stake in Omnicell in the second quarter valued at $2,476,000. Assenagon Asset Management S.A. increased its stake in Omnicell by 1,316.2% in the third quarter. Assenagon Asset Management S.A. now owns 140,675 shares of the company’s stock valued at $4,284,000 after purchasing an additional 130,742 shares in the last quarter. Capital Fund Management S.A. raised its holdings in shares of Omnicell by 97.1% during the second quarter. Capital Fund Management S.A. now owns 44,713 shares of the company’s stock valued at $1,315,000 after purchasing an additional 22,031 shares during the period. Finally, Systematic Financial Management LP bought a new position in shares of Omnicell during the 2nd quarter worth about $3,446,000. Institutional investors own 97.70% of the company’s stock.

Insider Activity at Omnicell

In other news, EVP Corey J. Manley sold 7,405 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $34.69, for a total value of $256,879.45. Following the completion of the sale, the executive vice president directly owned 96,717 shares of the company’s stock, valued at $3,355,112.73. This represents a 7.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.52% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on OMCL. Benchmark restated a “buy” rating on shares of Omnicell in a research note on Friday, March 13th. KeyCorp raised Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target on the stock in a research note on Wednesday, January 7th. UBS Group set a $60.00 price target on Omnicell and gave the stock a “buy” rating in a report on Friday, March 13th. Piper Sandler reissued an “overweight” rating and issued a $49.00 price objective (down from $63.00) on shares of Omnicell in a research note on Friday, February 6th. Finally, Wall Street Zen downgraded Omnicell from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Omnicell presently has a consensus rating of “Moderate Buy” and a consensus price target of $58.50.

Omnicell Stock Up 0.7%

Shares of NASDAQ OMCL opened at $35.20 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.43 and a quick ratio of 1.22. The company has a 50-day moving average price of $41.00 and a 200-day moving average price of $38.53. The stock has a market capitalization of $1.60 billion, a P/E ratio of 880.22, a P/E/G ratio of 1.25 and a beta of 0.79. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $55.00.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, February 5th. The company reported $0.40 earnings per share for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The business had revenue of $313.98 million during the quarter, compared to analyst estimates of $313.36 million. During the same quarter in the prior year, the company earned $0.60 EPS. The company’s revenue was up 2.3% on a year-over-year basis. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. On average, equities research analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.